Liquidia (LQDA) Share-based Compensation Growth (1y) (2021 - 2026)
Liquidia (LQDA) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.47% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 47.06% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.79% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 281.05% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 92.83% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 5.49% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 61.54% |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 23.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.92% |
| Dec 31, 2025 | 43.29% |
| Sep 30, 2025 | 61.81% |
| Jun 30, 2025 | 58.51% |
| Mar 31, 2025 | 64.41% |
| Dec 31, 2024 | 97.14% |
| Sep 30, 2024 | 96.26% |
| Jun 30, 2024 | 74.95% |
| Mar 31, 2024 | 77.27% |
| Dec 31, 2023 | 40.32% |
| Sep 30, 2023 | 50.91% |
| Jun 30, 2023 | 51.73% |
| Mar 31, 2023 | 60,879.69% |
| Dec 31, 2022 | -52.46% |
| Sep 30, 2022 | 34.64% |
| Jun 30, 2022 | 72.82% |
| Mar 31, 2022 | 461.74% |
| Dec 31, 2021 | 280.15% |
| Sep 30, 2021 | 13.23% |
| Jun 30, 2021 | -3.55% |